secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001193805-22-001230
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine
--------------------------------------------------------------------------------

- BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.
- Funding covers preclinical through Phase 1 clinical studies, including manufacturing and regulatory support.
- Candidate is lower-dose, freeze-dried vaccine; Arcturus' platform has been administered to over 10,000 individuals for SARS-CoV-2.
- Contract is terminable by BARDA at any time for convenience; no purchase of vaccine in scope.
- Award part of U.S. government's National Strategy for Pandemic Influenza to bolster pandemic preparedness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/0001193805-22-001230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001230/e621904_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer